<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474237</url>
  </required_header>
  <id_info>
    <org_study_id>1801-010-911</org_study_id>
    <nct_id>NCT03474237</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort Study for Patients With Adrenal Diseases</brief_title>
  <official_title>A Prospective Cohort Study for Patients With Adrenal Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pathologic features, complications, and
      prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for
      adrenal incidentaloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit 150 patients annually for 10 years (adrenal incidentaloma 100
      patients, pheochromocytoma 15 patients, primary aldosteronism 25 patients, adrenal cushing
      syndrome 10 patients, adrenocortical carcinoma 2 patients) and perform hormonal, biochemical,
      imaging exam according to each disease's clinical guidelines. Based on this, the
      investigators will identify pathologic features, complications, and prognostic factors of
      each disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants in remission</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Remission rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication of adrenal disease</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>all complications including deaths</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Adrenal Adenoma</condition>
  <condition>Cushing Syndrome</condition>
  <condition>Pheochromocytoma</condition>
  <condition>Adrenal Incidentaloma</condition>
  <condition>Adrenocortical Carcinoma</condition>
  <condition>Primary Hyperaldosteronism</condition>
  <arm_group>
    <arm_group_label>Non-functioning adrenal incidentaloma</arm_group_label>
    <description>patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pheochromocytoma</arm_group_label>
    <description>patients who were diagnosed with pheochromocytoma biochemically or histologically</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary aldosteronism</arm_group_label>
    <description>patients who were diagnosed with primary aldosteronism by saline loading test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adrenal cushing syndrome</arm_group_label>
    <description>patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adrenocortical carcinoma</arm_group_label>
    <description>patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hormone study and Imaging study</intervention_name>
    <description>Blood (basal hormone and follow up hormone study)
Imaging examination including computed tomography scan or magnetic resonance imaging</description>
    <arm_group_label>Non-functioning adrenal incidentaloma</arm_group_label>
    <arm_group_label>Pheochromocytoma</arm_group_label>
    <arm_group_label>Primary aldosteronism</arm_group_label>
    <arm_group_label>Adrenal cushing syndrome</arm_group_label>
    <arm_group_label>Adrenocortical carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        study population of this study is the patients who are newly diagnosed with adrenal disease
        such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing
        syndrome, adrenocortical carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, male or female aged 19 years or older

          -  newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma,
             primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma

        Exclusion Criteria:

          -  previous or current history of adrenal diseases

          -  using oral or intravenous steroids

          -  history of major depressive disorder

          -  history of chronic alcoholics

          -  history of any cancer with suspicious adrenal metastasis

          -  those with acute illness (ex- patients with acute coronary syndrome within 4 weeks,
             acute febrile disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Hee Kim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung Hee Kim, MD</last_name>
    <phone>82-2-2072-4073</phone>
    <email>jhkxingfu@gmail.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung Hee Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>algorithms</keyword>
  <keyword>adrenal adenoma</keyword>
  <keyword>cushing syndrome</keyword>
  <keyword>pheochromocytoma</keyword>
  <keyword>adrenal incidentaloma</keyword>
  <keyword>adreocortical carcinoma</keyword>
  <keyword>primary hyperaldosteronism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
    <mesh_term>Adrenal Gland Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

